Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.512 USD | +0.18% | -0.59% | -6.98% |
05-17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
04-02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.98% | 18.34M | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Transcript : Kala Pharmaceuticals, Inc., Q2 2020 Earnings Call, Aug 06, 2020